E
Elda Righi
Researcher at University of Verona
Publications - 168
Citations - 7444
Elda Righi is an academic researcher from University of Verona. The author has contributed to research in topics: Antibiotics & Antibiotic resistance. The author has an hindex of 37, co-authored 159 publications receiving 5568 citations. Previous affiliations of Elda Righi include Misericordia University & University of Genoa.
Papers
More filters
Journal ArticleDOI
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang,Jianping Yuan,Elda Righi,Walid S. Kamoun,Marek Ancukiewicz,Jean Nezivar,Michael Santosuosso,John D. Martin,Margaret R. Martin,Fabrizio Vianello,Pierre Leblanc,Lance L. Munn,Peigen Huang,Dan G. Duda,Dai Fukumura,Rakesh K. Jain,Mark C. Poznansky +16 more
TL;DR: It is demonstrated that targeting tumor vasculature with lower vascular-normalizing doses, but not high antivascular/antiangiogenic doses, of an anti-VEGF receptor 2 (VEGFR2) antibody results in a more homogeneous distribution of functional tumor vessels.
Journal ArticleDOI
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance A Randomized Clinical Trial
Patrick N A Harris,Patrick N A Harris,Patrick N A Harris,Paul A. Tambyah,David C. Lye,David C. Lye,David C. Lye,Yin Mo,Tau H. Lee,Tau H. Lee,Tau H. Lee,Mesut Yilmaz,Thamer H. Alenazi,Yaseen M. Arabi,Marco Falcone,Matteo Bassetti,Elda Righi,Benjamin A. Rogers,Souha S. Kanj,Hasan Bhally,Jon Iredell,Jon Iredell,Marc Mendelson,Tom H. Boyles,David Looke,David Looke,Spiros Miyakis,Spiros Miyakis,Spiros Miyakis,Genevieve Walls,Mohammed Al Khamis,Ahmed Zikri,Amy Crowe,Paul R. Ingram,Paul R. Ingram,Nick Daneman,Paul M. Griffin,Paul M. Griffin,Paul M. Griffin,Eugene Athan,Penelope Lorenc,Peter Baker,Leah W. Roberts,Scott A. Beatson,Anton Y. Peleg,Anton Y. Peleg,Tiffany Harris-Brown,David L. Paterson,David L. Paterson +48 more
TL;DR: Among patients with E coli or K pneumoniae bloodstream infection and ceftriaxone resistance, definitive treatment with piperacillin-tazobactam compared with meropenem did not result in a noninferior 30-day mortality, and findings do not support use of piperACillin- tazobactsam in this setting.
Journal ArticleDOI
How to manage Pseudomonas aeruginosa infections.
TL;DR: In this review, selected aspects of P. aeruginosa antimicrobial resistance and infection management will be addressed and clinical approaches to patients with bacteremia, ventilator-associated pneumonia, urinary tract infections and skin soft tissue infections are discussed.
Journal ArticleDOI
Epidemiological trends in nosocomial candidemia in intensive care.
Matteo Bassetti,Elda Righi,Alessandro Nanni Costa,R. Fasce,M. P. Molinari,Raffaella Rosso,Franco Bobbio Pallavicini,Claudio Viscoli +7 more
TL;DR: A shift in the species of Candida causing fungemia in a medical and surgical ICU population during a 5 year period is demonstrated, apparently correlated with an increasing use of azoles for prophylaxis or empirical treatment.
Journal ArticleDOI
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae.
Mario Tumbarello,Enrico Maria Trecarichi,Alberto Corona,Francesco Giuseppe De Rosa,Matteo Bassetti,Cristina Mussini,Francesco Menichetti,Claudio Viscoli,Caterina Campoli,Mario Venditti,Andrea De Gasperi,Alessandra Mularoni,Carlo Tascini,Giustino Parruti,Carlo Pallotto,Simona Sica,Ercole Concia,Rosario Cultrera,Gennaro De Pascale,Alessandro Capone,Spinello Antinori,Silvia Corcione,Elda Righi,Angela Raffaella Losito,Margherita Digaetano,Francesco Amadori,Daniele Roberto Giacobbe,Giancarlo Ceccarelli,E. Mazza,Francesca Raffaelli,Teresa Spanu,Roberto Cauda,Pierluigi Viale +32 more
TL;DR: CAZ-AVI appears to be a promising drug for treatment of severe KPC-Kp infections, especially those involving bacteremia, as well as hospital-acquired pneumonia, and for gram-negative infections with limited treatment options.